Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation

  • Technology appraisal guidance
  • TA429
  • Published: 

Tools and resources

Tools and resources to help you put the guidance into practice.

Resource impact

Guidance into practice